GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
GRAIL, Inc.NASDAQ: GRAL
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $38.69M fell 1.2% year over year, in line with the -1.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.
Context
- Depreciation & amortization amounted to 106.2% of revenue in FY2025, down 19.6 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -1.2% toward the trailing-twelve-month pace of -1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 156.34M USD
- Year-over-year change
- -1.1%
- 4-year CAGR
- +27.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 156.34M | -1.1% |
| FY2024 | 2024-12-31 | 158.06M | -0.4% |
| FY2023 | 2023-12-31 | 158.7M | +2.5% |
| FY2022 | 2022-12-31 | 154.76M | +164.8% |
| FY2021 | 2021-12-31 | 58.45M | — |
Depreciation & Amortization vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's LTM Jun 2026 depreciation & amortization of $155.37M is the largest of the 10 companies compared; the peer median is $26.88M.
- Its year-over-year change of -1.1% is the 4th highest of 9, against a peer median of -5.1%.
- Depreciation & amortization amounts to 94.0% of revenue for GRAL, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $155.37M | -1.1% | +0.3% | 94.0% | |
| LTM Jun 2026 | $65.8M | +87.5% | +37.6% | 2.4% | |
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $26.88M | +15.1% | -24.8% | 5.9% |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Mar 2026 | $14.94M | -64.8% | +57.0% | 4.4% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.3M | — | — | 3.1% |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| Peer median (excluding GRAL) | $26.88M | -5.1% | +2.0% | 5.9% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.25B) | (5.4B) | (1.47B) | (2.03B) | (408.35M) |
| Depreciation & Amortization | 58.45M | 154.76M | 158.7M | 158.06M | 156.34M |
| Deferred Income Tax | 0 | (39.06M) | (38.15M) | (134.25M) | (126.15M) |
| Stock-Based Compensation | 681.91M | 75.73M | 97.24M | 86.08M | 58.28M |
| Change in Working Capital | 21.59M | (14.46M) | 7.72M | (24.28M) | 12.41M |
| Accounts Receivables | (6.88M) | (8.68M) | (1.38M) | (3.37M) | 1.69M |
| Inventory | (5.67M) | (14.08M) | (1.94M) | 3.07M | 2.62M |
| Accounts Payables | 1.3M | 2.34M | 2.89M | (14.64M) | (2.73M) |
| Other Working Capital | 32.85M | 5.95M | 8.16M | (9.35M) | 10.84M |
| Other Non-Cash Items | (201M) | 4.66B | 644.39M | 1.36B | 8.46M |
| Operating Cash Flow | (688.13M) | (561.31M) | (595.8M) | (577.16M) | (299.01M) |
| Capital Expenditures | (69.93M) | (22.86M) | (12.89M) | (5.21M) | (909K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (545.8M) | (1.31B) |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.22B |
| Other Investing Activities | 414.74M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 344.81M | (22.86M) | (12.89M) | (551.01M) | (85.05M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.98M | 0 | 0 | 0 | 423.32M |
| Common Stock Repurchased | (170K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 388.93M | 604.82M | 463.77M | 1.24B | 0 |
| Financing Cash Flow | 394.74M | 604.82M | 463.77M | 1.24B | 423.32M |
| Effect of Forex Changes | (194.61M) | (511K) | 305K | (62K) | (147K) |
| Net Change in Cash | (143.19M) | 20.13M | (144.62M) | 116.07M | 39.12M |
| Free Cash Flow | (758.06M) | (584.17M) | (608.69M) | (582.36M) | (299.01M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.